Impact of epigenetic reprogramming on antitumor immune responses in glioma is a research paper published in Journal of Clinical Investigation (2023). On theSindex it has a DataRank of 0. It has been cited 67 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
NINDS NIH HHS
Grant: R01 NS076991
NINDS NIH HHS
Grant: R01 NS082311
NINDS NIH HHS
Grant: R01 NS096756
NINDS NIH HHS
Grant: R01 NS105556
NINDS NIH HHS
Grant: R01 NS122165
NINDS NIH HHS
Grant: R01 NS122234
NIAID NIH HHS
Grant: T32 AI007413
NINDS NIH HHS
Grant: R01 NS122536
NINDS NIH HHS
Grant: R21 NS123879
NINDS NIH HHS
Grant: R01 NS124167
NINDS NIH HHS
Grant: R37 NS094804
National Institutes of Health
Grant: 3R01NS105556-03S1
Interactions between the tumor cells and the neuro-immune microenvironment in mutant IDH1 gliomas: implications for therapeutics
National Institutes of Health
Grant: 1R01NS122165-01A1
Uncover the role of H3.3-G343R mutation in shaping the DNA damage response, anti-tumor immunity and mechanisms of resistance in glioma.
National Institutes of Health
Grant: 1R01NS082311-01
Mechanisms of glioma growth and invasion novel therapeutic strategies
National Institutes of Health
Grant: 1R21NS123879-01
Chemo-immunotherapy strategy for pediatric high grade glioma
National Institutes of Health
Grant: 5R01NS122234-02
The role of collagen and its signaling mechanisms in glioma progression and invasion.
National Institutes of Health
Grant: 5R01CA243916-04
Identifying intercellular circuits driving cell phenotypes within a niche
National Institutes of Health
Grant: 5R01NS076991-07
Novel Gene Therapy Strategies for Canavan Disease
National Institutes of Health
Grant: 3R01NS124167-04S1
Systemic Delivery of Targeted Bi-Compartmental Nanoparticles for Glioblastoma Therapeutics
National Institutes of Health
Grant: 1R01NS096756-01
Neuroimmunology of Malignant Brain Tumors: Innate Mechanisms
National Institutes of Health
Grant: 5R01NS122536-03
Novel nano-vaccine technology for inducing immunity against gliomas
National Institutes of Health
Grant: 5T32AI007413-27
Research Training in Experimental Immunology
National Institutes of Health
Grant: 5R37NS094804-06
Immune-suppressive Myeloid Cells in the Glioma Microenvironment: Signaling Mechanisms and Novel Therapeutic Strategies
FWCI
8.07
Citation Percentile
1.0%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals
Additional file 1 of Evaluation of the pooled sample method in Infinium MethylationEPIC BeadChip array by comparison with individual samples
Additional file 1 of Evaluation of the pooled sample method in Infinium MethylationEPIC BeadChip array by comparison with individual samples
Additional file 8 of Epigenetic remodeling to improve the efficacy of immunotherapy in human glioblastoma: pre-clinical evidence for development of new immunotherapy approaches
Additional file 8 of Epigenetic remodeling to improve the efficacy of immunotherapy in human glioblastoma: pre-clinical evidence for development of new immunotherapy approaches
Additional file 4 of Evaluation of the pooled sample method in Infinium MethylationEPIC BeadChip array by comparison with individual samples
Additional file 3 of Evaluation of the pooled sample method in Infinium MethylationEPIC BeadChip array by comparison with individual samples
Additional file 2 of Evaluation of the pooled sample method in Infinium MethylationEPIC BeadChip array by comparison with individual samples
Additional file 2 of Evaluation of the pooled sample method in Infinium MethylationEPIC BeadChip array by comparison with individual samples
Additional file 3 of Evaluation of the pooled sample method in Infinium MethylationEPIC BeadChip array by comparison with individual samples
Additional file 4 of Evaluation of the pooled sample method in Infinium MethylationEPIC BeadChip array by comparison with individual samples
Additional file 6 of Epigenetic remodeling to improve the efficacy of immunotherapy in human glioblastoma: pre-clinical evidence for development of new immunotherapy approaches
Additional file 7 of Epigenetic remodeling to improve the efficacy of immunotherapy in human glioblastoma: pre-clinical evidence for development of new immunotherapy approaches
Additional file 7 of Epigenetic remodeling to improve the efficacy of immunotherapy in human glioblastoma: pre-clinical evidence for development of new immunotherapy approaches
Additional file 6 of Epigenetic remodeling to improve the efficacy of immunotherapy in human glioblastoma: pre-clinical evidence for development of new immunotherapy approaches
Additional file 4 of Epigenetic remodeling to improve the efficacy of immunotherapy in human glioblastoma: pre-clinical evidence for development of new immunotherapy approaches
Additional file 5 of Epigenetic remodeling to improve the efficacy of immunotherapy in human glioblastoma: pre-clinical evidence for development of new immunotherapy approaches
Additional file 5 of Epigenetic remodeling to improve the efficacy of immunotherapy in human glioblastoma: pre-clinical evidence for development of new immunotherapy approaches
Additional file 4 of Epigenetic remodeling to improve the efficacy of immunotherapy in human glioblastoma: pre-clinical evidence for development of new immunotherapy approaches
Additional file 1 of Epigenetic remodeling to improve the efficacy of immunotherapy in human glioblastoma: pre-clinical evidence for development of new immunotherapy approaches
Additional file 2 of Epigenetic remodeling to improve the efficacy of immunotherapy in human glioblastoma: pre-clinical evidence for development of new immunotherapy approaches